CEFTRIAXONE INJECTION, USP SOLUTION

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

CEFTRIAXONE (CEFTRIAXONE SODIUM)

Prieinama:

BAXTER CORPORATION

ATC kodas:

J01DD04

INN (Tarptautinis Pavadinimas):

CEFTRIAXONE

Dozė:

2000MG

Vaisto forma:

SOLUTION

Sudėtis:

CEFTRIAXONE (CEFTRIAXONE SODIUM) 2000MG

Vartojimo būdas:

INTRAVENOUS

Vienetai pakuotėje:

15G/50G

Recepto tipas:

Prescription

Gydymo sritis:

THIRD GENERATION CEPHALOSPORINS

Produkto santrauka:

Active ingredient group (AIG) number: 0117292012; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2020-06-02

Prekės savybės

PRODUCT MONOGRAPH
Including Patient Medication Information
PR
CEFTRIAXONE INJECTION, USP
CEFTRIAXONE (AS CEFTRIAXONE SODIUM USP)
1000 MG / 50 ML AND 2000 MG / 50 ML IN SINGLE DOSE GALAXY CONTAINERS
READY-TO-USE
STERILE SOLUTION (FROZEN)
ANTIBIOTIC
BAXTER CORPORATION
7125 Mississauga Road
Mississauga, Ontario
L5N 0C2
CONTROL #: 215096
Date of Preparation: May 28, 2020
BAXTER AND GALAXY ARE REGISTERED TRADEMARKS OF BAXTER
INTERNATIONAL INC.
Ceftriaxone Injection, USP
Page 2 of 52
TABLE OF CONTENTS
HEALTH PROFESSIONAL INFORMATION
.........................................................................
3
ACTION
......................................................................................................................................
3
INDICATIONS AND CLINICAL USES
...................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
4
WARNINGS
...............................................................................................................................
4
PRECAUTIONS
.........................................................................................................................
7
ADVERSE REACTIONS
...........................................................................................................
8
SYMPTOMS AND TREATMENT OF OVERDOSAGE
........................................................ 10
DOSAGE AND ADMINISTRATION
.....................................................................................
10
ADMINISTRATION
................................................................................................................
11
SPECIAL HANDLING INSTRUCTIONS
...............................................................................
12
PHARMACEUTICAL INFORMATION
.................................................................................
13
DRUG SUBSTANCE
.................................................................